SEC Form 4 · accession 0001185185-17-000388
Entia Biosciences, Inc. · ERGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carl J Johnson
Officer — President and CEO · Director
Period of report
Feb 14, 2017
Accepted (ET)
Feb 16, 2017 · 5:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001408299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 14, 2017 | A | 300,000 | $0.00 | A | 300,000 | D | |
| Common Stock | Feb 14, 2017 | A | 300,000 | $0.00 | A | 600,000 | D | |
| Common Stock | Feb 16, 2017 | A | 250,000 | $0.00 | A | 850,000 | D |
Table II — derivative securities
No Table II lines on this filing.